Vanguard Group Inc. Grows Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Vanguard Group Inc. increased its position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 5.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,373,039 shares of the company's stock after purchasing an additional 460,753 shares during the period. Vanguard Group Inc. owned about 2.20% of GoodRx worth $38,935,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GDRX. LPL Financial LLC boosted its position in GoodRx by 93.9% during the 4th quarter. LPL Financial LLC now owns 46,320 shares of the company's stock worth $215,000 after acquiring an additional 22,436 shares during the period. KLP Kapitalforvaltning AS purchased a new position in GoodRx during the fourth quarter valued at approximately $358,000. Virtu Financial LLC acquired a new position in GoodRx in the 4th quarter valued at approximately $107,000. Quantbot Technologies LP lifted its position in GoodRx by 497.2% in the 4th quarter. Quantbot Technologies LP now owns 109,434 shares of the company's stock worth $509,000 after buying an additional 91,111 shares in the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new position in GoodRx in the fourth quarter valued at about $1,310,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GDRX has been the subject of a number of analyst reports. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Citigroup reduced their price objective on GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Truist Financial reduced their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. Wells Fargo & Company reduced their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Morgan Stanley decreased their price objective on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.93.

Remove Ads

GoodRx Stock Performance

Shares of GDRX stock remained flat at $4.49 during trading hours on Tuesday. 747,078 shares of the stock traded hands, compared to its average volume of 1,379,576. The company's fifty day simple moving average is $4.64 and its 200 day simple moving average is $5.03. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -149.67, a P/E/G ratio of 2.46 and a beta of 1.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx Holdings, Inc. has a one year low of $3.82 and a one year high of $9.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.